Chenodeoxycholic Acid
Approved · EMAAlso known as 3alpha,7alpha-Dihydroxy-5beta-cholanic acid, Acide chenodeoxycholique, Acido chenodeoxicholico, Acidum chenodeoxycholicum+10 more
3alpha,7alpha-Dihydroxy-5beta-cholanic acid, Acide chenodeoxycholique, Acido chenodeoxicholico, Acidum chenodeoxycholicum, Anthropodeoxycholic acid, Anthropodesoxycholic acid, CDCA, CDCA - chenodeoxycholic acid, CHENODIOL, Chenic acid, Chenocholic acid, Gallodesoxycholic acid, Chenodesoxycholic acid, 3 alpha,7 alpha, dihydroxycholanic acid.
Recent clinical, regulatory, research and industry developments relating to this drug.
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility.
Approval: Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) (EMA)
Biologic Significance of Cholestanol in Man
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous… Show full indicationShow less
Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
Recent completions
Trials that read out recently, adding to the completed evidence base.
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- EBioMedicine1
- Nature communications1
- Bian Z2
- Han X2
- Huang F2
- Jia W2
- Li M2
- Rajani C2
- Wang S2
- Wei M2
- Chinese Medicine Clinical Study Center1
- Functional Metabolomic and Gut Microbiome Laboratory1
- School of Chinese Medicine1
- School of Pharmacy1
- Shanghai Jiao Tong University Affiliated Six People's Hospital1
- Shanghai Key Laboratory of Diabetes Mellitus and Center for Translational Medicine1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Chenodeoxycholic Acid, with 3 overlapping disease areas.
Studied across 3 of the same disease areas as Chenodeoxycholic Acid in the shared literature.
Studied across 2 of the same disease areas as Chenodeoxycholic Acid in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.